Phase 2 trial of leuprorelin in patients with spinal and bulbar muscular atrophy-Reference-Cited by-同舟云学术

Phase 2 trial of leuprorelin in patients with spinal and bulbar muscular atrophy

Published:2009-02 Issue:2 Volume:65 Page:140-150
ISSN:0364-5134
Container-title:Annals of Neurology
language:en
Short-container-title:Ann Neurol.

Author:

Banno Haruhiko,Katsuno Masahisa,Suzuki Keisuke,Takeuchi Yu,Kawashima Motoshi,Suga Noriaki,Takamori Motoko,Ito Mizuki,Nakamura Tomohiko,Matsuo Koji,Yamada Shinichi,Oki Yumiko,Adachi Hiroaki,Minamiyama Makoto,Waza Masahiro,Atsuta Naoki,Watanabe Hirohisa,Fujimoto Yasushi,Nakashima Tsutomu,Tanaka Fumiaki,Doyu Manabu,Sobue Gen

Publisher

Wiley

Subject

Neurology (clinical),Neurology

Reference51 articles.

1. Progressive proximal spinal and bulbar muscular atrophy of late onset. A sex-linked recessive trait;Kennedy;Neurology,1968

2. X-linked bulbospinal neuronopathy: Kennedy disease;Sperfeld;Arch Neurol,2002

3. X-linked recessive bulbospinal neuronopathy. A clinicopathological study;Sobue;Brain,1989

4. Spinal and bulbar muscular atrophy: ligand-dependent pathogenesis and therapeutic perspectives;Katsuno;J Mol Med,2004

5. Kennedy disease;Fischbeck;J Inherit Metab Dis,1997

Cited by 132 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mutant androgen receptor induces neurite loss and senescence independently of ARE binding in a neuronal model of SBMA;Proceedings of the National Academy of Sciences;2024-07-08

2. 271st ENMC international workshop: Towards a unifying effort to fight Kennedy's disease. 20-22 October 2023, Hoofddorp, Netherlands;Neuromuscular Disorders;2024-05

3. Polyglutamine disease proteins: Commonalities and differences in interaction profiles and pathological effects;PROTEOMICS;2024-04-14

4. Efficacy of leuprorelin in spinal and bulbar muscular atrophy: a 3-year observational study;Neurological Sciences;2024-02-24

5. Spinal and bulbar muscular atrophy: From molecular pathogenesis to pharmacological intervention targeting skeletal muscle;Current Opinion in Pharmacology;2023-08